VRVincent Ribrag

Vincent Ribrag

*This is an algorithmically generated author record based on publicly available information.

Vincent Ribrag has a total of 139 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years

    by Maxime Jullien, Benoit Tessoulin, Hervé Ghesquières, Lucie Oberic, Franck Morschhauser, Hervé Tilly, Vincent Ribrag, Thierry Lamy, Catherine Thieblemont, Bruno Villemagne, et al.

    Background. Muscle depletion (MD) assessed by computed tomography (CT) has been shown to be a predictive marker in solid tumors, but has not been assessed in non-Hodgkin’s lymphomas. Despite software improvements, MD measurement remains highly time-consuming and cannot be used in clinical practice. Methods. This study reports the development of a Deep-Learning automatic segmentation algorithm (DLASA) to measure MD, and investigate its predictive value in a cohort of 656 diffuse large B cell lymphoma (DLBCL) patients included in the GAINED phase III prospective trial (NCT01659099). Results. After training on a series of 190 patients, the DLASA achieved a Dice coefficient of 0.97 ± 0.03. In the cohort, the median skeletal muscle index was 50.2 cm2/m2 and median muscle attenuation (MA) was 36.1 Hounsfield units (HU). No impact of sarcopenia was found on either progression free survival (PFS) or overall survival (OS). Muscular hypodensity, defined as MA below the tenth percentile according to sex, was associated with a lower OS and PFS, respectively (HR = 2.80 (95% CI 1.58–4.95), p < 0.001, and HR = 2.22 (95% CI 1.43–3.45), p < 0.001). Muscular hypodensity appears to be an independent risk factor for mortality in DLBCL and because of DLASA can be estimated in routine practice.


  • Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study.

    by Nicolas Mounier, Sabine Anthony, Raphael Busson, Catherine Thieblemont, Virginie Nerich, Vincent Ribrag, Marie Castera, Herve Tilly, Corinne Haioun, Rene-Olivier Casasnovas, et al.

    7518 Background: NHL survivors are at high risk for second cancers (SC) and late toxicities such as cardiovascular (CV) or neuro-psychiatric (NP) disorders. Little is known about new agents such as rituximab (RITUX). The impact of treatment regimens on late morbidity was analyzed in a large cohort of survivors with long follow-up (FU). Methods: In 2015, a fatigue (MFI-20) and a self-assessment Life Situation Questionnaire (LSQ) were mailed to survivors treated in 12 successive LYSA randomized trials (1993-2007) for Diffuse Large B cell (DLBCL) and follicular (FL) lymphomas. Of 8113 pts enrolled into trials, 5247 were alive at last FU. Addresses were obtained for 3317 survivors of whom 1671 (50%) returned the questionnaires. Responders more often came from recent trials and were more often treated with RITUX than non-responders. NHL prognostic factors and chemotherapy were similar in both groups. Linear regression models were used to assess factors linked to increased fatigue level. Results: There were 906 males and 765 females (median age 64 yrs; 24 to 95). 28% had FL and 72% DLBCL. 811 pts received CHOP-like chemotherapy, 518 high-dose CHOP and 342 up-front autograft consolidation (ASCT). RITUX was combined to chemotherapy in 829 pts (50%). Median FU was 11 yrs (5 to 23). 583 pts (35%) reported no morbidity. For the remaining, late events (1 to 7) were: CV in 20%, NP in 17%, infections in 12%, musculoskeletal (MSk) disorders in 11%, pulmonary (Pulm) diseases in 8%, digestive diseases in 5% and SC in 8%. RITUX was associated with less SC (6 vs 9%, p = 0.02) and less CV (17 vs 23%, p = 0.006). Up-front ASCT was associated with more infections (17 vs 11%, p = 0.002) and more Pulm (12 vs 7%, p = 0.005). Age above 75 (20%) was only associated with more CV and more SC. 1036 pts (64%) expressed persistent fatigue (MFI score ≥ 40). There were no significant impact of any treatments. Increased fatigue level was associated (p < 0.001) with age, obesity, CV, Pulm, MSk and NP. Conclusions: This first study reporting on long-term NHL survivors confirmes an altered health status. Initial combination of chemotherapy and RITUX does not increase late morbidity and fatigue. Clinical trial information: pooled trials already registred.


  • The NF-κB pathway is rarely spontaneously activated in mantle cell lymphoma (MCL) cell lines and patient’s samples

    by V. Camara-Clayette, Y. Lecluse, C. Schrader, W. Klapper, W. Vainchenker, O. Hermine, V. Ribrag


  • Open Access

    BMP7 Expression Correlates with Secondary Drug Resistance in Mantle Cell Lymphoma

    by Valérie Camara-Clayette, Serge Koscielny, Sébastien Roux, Thierry Lamy, Jacques Bosq, Marc Bernard, Thierry Fest, Vladimir Lazar, Gilbert Lenoir, Vincent Ribrag

    We designed a gene profiling experiment to identify genes involved in secondary drug resistance in mantle cell lymphomas (MCL). We obtained paired tissue samples collected from the same patients before treatment and after relapse or progression. Variations in gene expression between the 2 samples were estimated for 5 patients. For each gene, the mean variation was estimated for patients with a refractory primary tumor and for responders who developed secondary drug resistance. Nine genes of interest were selected on the basis of the magnitude and statistical significance of the variation of expression in responders and non-responders. BMP7 was the only one with significantly increased expression at relapse in patients who developed secondary resistance. Validation of BMP7 as a key gene involved in secondary resistance was performed using cultures of cell line. Incubation of BMP7 with MCL cell lines increased their resistance to bortezomib and cytarabine, while inhibition of BMP7 expression by siRNA correlated with increased cell death linked to drug application. Variations in gene expression after treatment point out BMP7 as a key gene involved in secondary resistance in mantle cell lymphoma.


  • Plitidepsin: an orphan drug

    by Alina Danu, Christophe Willekens, Vincent Ribrag

    Introduction: Plitidepsin (Aplidin®) is a second-generation didemnin compound that belongs to drugs derived from natural oceanic products. Areas covered: In this review, the authors present the preclinical and clinical data available on this specific marine drug. In vitro and in vivo experiments showed that plitidepsin was active against many tumor models and was able to induce cell cycle arrest at low doses, apoptosis and also had antiangiogenic properties suggesting that this drug may be active in a broad range of human tumors. Phase I trials showed that the drug could be administrated in short or prolonged infusions, with a safety profile much more acceptable than the parent didemnin B molecule. Dose-limiting toxicities were hepatic (cytolysis) and muscular, but were manageable and reversible. No significant bone marrow toxicity was observed. Clinical activity was observed in many tumor types in Phase I that was not reproducible in a high proportion of cases in Phase II. Expert opinion: In hematology, plitidepsin is active in peripheral T-cell lymphomas (ORR 20.7%), but not in B-cell lymphomas suggesting a specific activity in T-cell proliferation especially in AILD where complete remissions were observed in monotherapy. Given the safety profile of this drug, combination trials could be further tested in this rare and serious lymphoma entity.


  • Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: A randomised phase II trial from the Groupe d’Etude des Lymphomes de l’Adulte (GELA)

    by Vincent Ribrag, Hervé Tilly, Olivier Casasnovas, André Bosly, Reda Bouabdallah, Richard Delarue, François Boue, Dominique Bron, Pierre Feugier, Corinne Haioun, et al.


  • Open Access

    Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma

    by V. Ribrag, D. Caballero, C. Ferme, E. Zucca, R. Arranz, J. Briones, C. Gisselbrecht, G. Salles, A. M. Gianni, H. Gomez, et al.

    This phase II clinical trial evaluated the efficacy, safety and pharmacokinetics of plitidepsin 3.2 mg/m2 administered as a 1-hour intravenous infusion weekly on days 1, 8 and 15 every 4 weeks in 67 adult patients with relapsed/refractory aggressive non-Hodgkin’s lymphoma. Patients were divided into two cohorts: those with non-cutaneous peripheral T-cell lymphoma (n=34) and those with other lymphomas (n=33). Efficacy was evaluated using the International Working Group criteria (1999). Of the 29 evaluable patients with non-cutaneous peripheral T-cell lymphoma, six had a response (overall response rate 20.7%; 95% confidence interval, 8.0%–39.7%), including two complete responses and four partial responses. No responses occurred in the 30 evaluable patients with other lymphomas (including 27 B-cell lymphomas). The most common plitidepsin-related adverse events were nausea, fatigue and myalgia (grade 3 in (clinicaltrials.gov identifier: NCT00884286)


  • Methotrexate- and/or cytarabine-based chemotherapy may be effective and safe in solid-organ transplant recipients with primary central nervous system lymphomas

    by Laura Moise, Clemence Matta, Colette Hanna, Sylvain Pilorge, Christophe Fermé, Antoine Durrbach, Vincent Ribrag


  • Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis

    by Vincent Ribrag, Serge Koscielny, Olivier Casasnovas, Cecile Cazeneuve, Pauline Brice, Franck Morschhauser, Jean Gabarre, Aspasia Stamatoullas, Gilbert Lenoir, Gilles Salles

    Hodgkin lymphoma is a highly curable malignancy, but treatment outcome might be influenced by inherited gene polymorphisms determining anticancer agent metabolism. We prospectively collected peripheral blood lymphocytes from 313 patients with Hodgkin lymphomas to analyze GSTP1, GSTM1, GSTT1, UGT1A1, and CYP3A4 enzyme gene polymorphisms. All patients were treated with chemotherapy, associated with radiotherapy when they had localized disease. There was no difference for GSTP1, GSTM1, and GSTT1 as well as for UGT1A1 and CYP3A4 polymorphism distributions between Hodgkin lymphoma patients and healthy controls. Patients carrying 1 or 2 UGT1A1*28 allele had a significantly (P < .05) better freedom from progression and time to treatment failure than those homozygous for the UGT1A1 TA6/TA6 allele. Multivariate prognostic analyses showed that the UGT1A1 polymorphism was as an independent prognostic parameter for all the studied endpoints, the wild-type homozygous UGT1A1 TA6/TA6 genotype being associated with a significantly worse prognosis than genotypes with at least one UGT1A1*28 allele (overall survival; relative risk [RR] = 2.54, 95% confidence interval [CI], 1.05-6.14; P = .04; freedom from progression, RR = 2.70, 95% CI, 1.37-5.31; P = .004; time to treatment failure, RR = 2.37, 95% CI, 1.28-4.40, P = .006). UGT1A1 polymorphism on TA repeats, which are thought to determine several anticancer drugs metabolism, influence Hodgkin lymphoma patient outcome.